Kymera Therapeutics, Inc. $KYMR Holdings Reduced by First Turn Management LLC

First Turn Management LLC decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 25.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 206,445 shares of the company’s stock after selling 71,281 shares during the period. Kymera Therapeutics makes up approximately 1.8% of First Turn Management LLC’s investment portfolio, making the stock its 26th largest position. First Turn Management LLC’s holdings in Kymera Therapeutics were worth $16,063,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of KYMR. Smartleaf Asset Management LLC grew its position in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC grew its position in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. grew its position in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Bessemer Group Inc. grew its position in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the 4th quarter worth about $63,000.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $86.21 on Friday. The firm has a 50 day simple moving average of $82.85 and a 200-day simple moving average of $80.22. The stock has a market capitalization of $7.09 billion, a PE ratio of -24.15 and a beta of 2.02. Kymera Therapeutics, Inc. has a 12-month low of $36.65 and a 12-month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same period last year, the firm posted ($0.82) earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. On average, analysts forecast that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the subject of several recent analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Canaccord Genuity Group started coverage on shares of Kymera Therapeutics in a report on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price objective for the company. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Citigroup increased their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $117.14.

Insider Activity

In related news, Director Bruce Booth sold 5,900 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the sale, the director owned 5,641 shares in the company, valued at approximately $507,464.36. This represents a 51.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Elena Ridloff sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $87.00, for a total transaction of $261,000.00. Following the completion of the sale, the director owned 3,000 shares of the company’s stock, valued at approximately $261,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 234,357 shares of company stock worth $19,072,496 in the last quarter. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.